Abstract
Synergy between HIV and malaria is being increasingly recognized. We examined the antimalarial activity of sera from subjects receiving chloroquine, no drugs or HAART. Sera from subjects taking ritonavir-boosted saquinavir or lopinavir significantly inhibited parasite growth (median of 55 and 69% inhibition, respectively). These results indicate that patients on protease inhibitors may be afforded some protection from malaria. The clinical relevance of these observations will require confirmation in controlled studies in malaria-endemic regions.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antimalarials / therapeutic use*
-
Antiretroviral Therapy, Highly Active / methods
-
Chloroquine / therapeutic use
-
Drug Synergism
-
HIV Infections / blood
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / therapeutic use*
-
Humans
-
Lopinavir
-
Malaria, Falciparum / blood
-
Malaria, Falciparum / complications
-
Malaria, Falciparum / drug therapy*
-
Plasmodium falciparum / drug effects
-
Plasmodium falciparum / growth & development
-
Pyrimidinones / therapeutic use
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Ritonavir / therapeutic use
-
Saquinavir / therapeutic use
-
Treatment Outcome
Substances
-
Antimalarials
-
HIV Protease Inhibitors
-
Pyrimidinones
-
Reverse Transcriptase Inhibitors
-
Lopinavir
-
Chloroquine
-
Saquinavir
-
Ritonavir